• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯妥英钠:蛋白结合与白蛋白浓度之间的相关性。

Diphenylhydantoin: correlation between protein binding and albumin concentration.

作者信息

Gugler R, Azarnoff D L, Shoeman D W

出版信息

Klin Wochenschr. 1975 May 1;53(9):445-6. doi: 10.1007/BF01493371.

DOI:10.1007/BF01493371
PMID:1152355
Abstract

The unbound fraction of diphenylhydantoin is inversely correlated with the patient's serum albumin concentration and can be accurately estimated graphically without binding analyses. The data for this relationship was obtained from a study in which we observed that the unbound fraction of diphenylhydantoin was two times higher in patients with the nephrotic syndrome. However, in these patients it was not necessary to diminish the dosage since the absolute concentration of unbond drug was unchanged due to a compensatory increase in the apparent volume of distribution and plasma clearance.

摘要

苯妥英的游离分数与患者的血清白蛋白浓度呈负相关,且无需进行结合分析即可通过图表准确估算。这种关系的数据来自一项研究,在该研究中我们观察到,肾病综合征患者的苯妥英游离分数高出两倍。然而,在这些患者中无需减少剂量,因为由于表观分布容积和血浆清除率的代偿性增加,游离药物的绝对浓度并未改变。

相似文献

1
Diphenylhydantoin: correlation between protein binding and albumin concentration.苯妥英钠:蛋白结合与白蛋白浓度之间的相关性。
Klin Wochenschr. 1975 May 1;53(9):445-6. doi: 10.1007/BF01493371.
2
Drug protein binding and the nephrotic syndrome.药物蛋白结合与肾病综合征
Clin Pharmacokinet. 1976;1(1):25-35. doi: 10.2165/00003088-197601010-00003.
3
Plasma albumin concentration and diphenylhydantoin binding in man.人体血浆白蛋白浓度与苯妥英钠结合情况
Arch Neurol. 1975 May;32(5):298-303. doi: 10.1001/archneur.1975.00490470042005.
4
Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury.脑损伤后急性期和恢复期苯妥英的蛋白结合及剂量需求
Ann Pharmacother. 1996 May;30(5):443-8. doi: 10.1177/106002809603000501.
5
Pharmacokinetics of drugs in patients with the nephrotic syndrome.肾病综合征患者的药物药代动力学
J Clin Invest. 1975 Jun;55(6):1182-9. doi: 10.1172/JCI108035.
6
Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.苯妥英在尿毒症患者中的动力学:血浆蛋白结合降低的后果
Eur J Clin Pharmacol. 1974;7(1):31-7. doi: 10.1007/BF00614387.
7
Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.药物代谢随年龄增长的变化:2. 苯妥英钠清除率与蛋白结合率
Br J Clin Pharmacol. 1975 Feb;2(1):73-9. doi: 10.1111/j.1365-2125.1975.tb00475.x.
8
Furosemide binding to human albumin and plasma of nephrotic children.呋塞米与肾病患儿人白蛋白及血浆的结合
Clin Pharmacol Ther. 1975 Feb;17(2):159-65. doi: 10.1002/cpt1975172159.
9
Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration.丙戊酸钠合并用药患者的游离苯妥英血浆浓度——血浆白蛋白浓度的预测价值
Br J Clin Pharmacol. 1989 Jun;27(6):843-9. doi: 10.1111/j.1365-2125.1989.tb03448.x.
10
Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome.速尿在肾病综合征患者中的药代动力学及效应
Eur J Clin Pharmacol. 1989;37(2):173-80. doi: 10.1007/BF00558227.

引用本文的文献

1
Patient resuscitated after cardiopulmonary arrest exhibits abnormally increased phenytoin metabolic rate due to unknown factors: a case report.心肺骤停后复苏的患者因不明因素出现苯妥英代谢率异常升高:一例报告
J Pharm Health Care Sci. 2024 Aug 28;10(1):53. doi: 10.1186/s40780-024-00374-6.
2
Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.托格列净和依帕列净治疗2型糖尿病患者的疗效和安全性:一项通过动态血糖监测进行的随机交叉研究
Diabetes Ther. 2020 Dec;11(12):2945-2958. doi: 10.1007/s13300-020-00940-9. Epub 2020 Oct 15.
3

本文引用的文献

1
INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.羟化不足作为苯妥英钠毒性的一个原因
Neurology. 1964 Jun;14:542-8. doi: 10.1212/wnl.14.6.542.
2
SERUM DIPHENYLHYDANTOIN (PHENYTOIN) IN AMBULANT PATIENTS WITH EPILEPSY.
Epilepsia. 1964 Mar;5:51-8. doi: 10.1111/j.1528-1157.1964.tb04345.x.
3
[The significance of cumulation and elimination for the determination of Phenytoin (diphenylhydantoin)].[蓄积与消除对苯妥英钠(二苯乙内酰脲)测定的意义]
Dtsch Med Wochenschr. 1969 Jun 13;94(24):1265-72. doi: 10.1055/s-0028-1111205.
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.
肾移植术后早期霉酚酸的药代动力学及相关结果
Br J Clin Pharmacol. 2005 Mar;59(3):271-80. doi: 10.1111/j.1365-2125.2004.02235.x.
4
The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.将EMIT FreeLevel超滤技术与平衡透析法和超速离心法进行比较,以测定苯妥英的蛋白结合率。
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:61-70. doi: 10.2165/00003088-198400091-00008.
5
Free drug concentration monitoring in clinical practice. Rationale and current status.临床实践中的游离药物浓度监测。原理与现状。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69. doi: 10.2165/00003088-198611060-00003.
6
Effect of albumin distribution. A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs.
Pharm Weekbl Sci. 1989 Jun 23;11(3):87-91. doi: 10.1007/BF02110255.
7
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).疾病引起的血浆蛋白水平变化。对药物给药方案的影响(第二部分)。
Clin Pharmacokinet. 1990 Sep;19(3):218-29. doi: 10.2165/00003088-199019030-00005.
8
Drug protein binding and the nephrotic syndrome.药物蛋白结合与肾病综合征
Clin Pharmacokinet. 1976;1(1):25-35. doi: 10.2165/00003088-197601010-00003.
9
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.健康受试者和肾病患者中丙戊酸的血浆蛋白结合情况。
Br J Clin Pharmacol. 1978 May;5(5):441-6. doi: 10.1111/j.1365-2125.1978.tb01652.x.
4
The rate of decline of diphenylhydantoin in human plasma.人体血浆中苯妥英的下降速率。
Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121-34. doi: 10.1002/cpt1970111121.
5
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.
Pharmacology. 1972;7(3):169-77. doi: 10.1159/000136286.
6
Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.癫痫患者中苯妥英钠的血浆蛋白结合。血浆中游离分数与脑脊液浓度之间的一致性。
Clin Pharmacol Ther. 1972 Mar-Apr;13(2):196-200. doi: 10.1002/cpt1972132196.
7
Erythrocyte uptake and plasma binding of diphenylhydantoin.
Clin Pharmacol Ther. 1974 Aug;16(2):355-62. doi: 10.1002/cpt1974162355.
8
Antiserum to diphenylhydantoin: preparation and characterization.苯妥英抗血清:制备与特性鉴定
Res Commun Chem Pathol Pharmacol. 1973 May;5(3):767-74.
9
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.人体内苯妥英钠的血浆蛋白结合。与其他药物的相互作用以及温度和血浆稀释的影响。
Clin Pharmacol Ther. 1970 Nov-Dec;11(6):846-55. doi: 10.1002/cpt1970116846.
10
Biochemical and genetic factors regulating dilantin metabolism in man.
Ann N Y Acad Sci. 1971 Jul 6;179:705-22. doi: 10.1111/j.1749-6632.1971.tb46946.x.